Advanced search
Publication Cover
Current Medical Research and Opinion Volume 24, 2008 - Issue 7
Submit an article Journal homepage
938
Views
82
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study*

Álvaro Réa-Neto Hospital de Clínicas da Universidade Federal do Paraná, Rua General Carneiro, Curitiba, BrasilCorrespondence[email protected]
,
Michael Niederman Winthrop-University Hospital, Mineola, NY, USA
,
Suzana Margareth Lobo Hospital de Base da Faculdade de Medicina de São José do Rio Preto, Rua Brigadeiro Faria Lima, São Paulo, Brasil
,
Eric Schroeder Consultants in Pulmonary Medicine, Olathe, KS, USA
,
Michael Lee Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA
,
Koné Kaniga Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA
,
Nzeera Ketter Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA
,
Philippe Prokocimer Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA; Currently Chief Medical Officer, Trius Therapeutics, San Diego, CA, USA
&
Ian Friedland Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA
 show all
Pages 2113-2126 | Accepted 06 May 2008, Published online: 11 Jun 2008

Citations (82)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Joaquin Burgos, Vicenç Falcó & Benito Almirante. (2019) Chemical pharmacotherapy for hospital-acquired pneumonia in the elderly. Expert Opinion on Pharmacotherapy 20:4, pages 423-434.
Read now
Dominique Breilh, Jeannette Texier-Maugein, Bernard Allaouchiche, Marie-Claude Saux & Emmanuel Boselli. (2013) Carbapenems. Journal of Chemotherapy 25:1, pages 1-17.
Read now
Yoshiro Hayashi, Jason A Roberts, David L Paterson & Jeffrey Lipman. (2010) Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opinion on Drug Metabolism & Toxicology 6:8, pages 1017-1031.
Read now
Gina Devasahayam, William M Scheld & Paul S Hoffman. (2010) Newer antibacterial drugs for a new century. Expert Opinion on Investigational Drugs 19:2, pages 215-234.
Read now
Thitima Kongnakorn, Mkaya Mwamburi, Sanjay Merchant, Kasem Akhras, J. Jaime Caro & Dilip Nathwani. (2010) Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Current Medical Research and Opinion 26:1, pages 17-24.
Read now
Stephen G. Jenkins, Alan C. Fisher, Janet A. Peterson, Susan C. Nicholson & Koné Kaniga. (2009) Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Current Medical Research and Opinion 25:12, pages 3029-3036.
Read now
Francisco Alvarez-Lerma, Santiago Grau & Olivia Ferrández. (2009) Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Design, Development and Therapy 3, pages 173-190.
Read now
Tze Shien Lo, Stephanie M Borchardt, Justin M Welch, Melissa A Rohrich, Augusto M Alonto & Anne V Alonto. (2009) Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections. Infection and Drug Resistance 2, pages 41-49.
Read now

Articles from other publishers (74)

Nicole F. MaranchickCesar Trillo-AlvarezVidhu Kariyawasam, Veena VenugopalanAwewura Kwara, Kenneth RandCharles A. PeloquinMohammad H. Alshaer. (2023) A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia. Therapeutic Drug Monitoring.
Crossref
Huai Qin Cang, Xiang Hua Quan, Xiang Hua Chu, Yu Liang, Xue Yang & Jing Li. (2023) Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis. Heliyon 9:10, pages e20108.
Crossref
Meng-Hsuan Lin, Yi-Cheng Shen, Han-Yun Cheng, Chi-Kang Teng, Wei-Cheng Chen, Yu-Chao Lin & Chin-Chuan Hung. (2023) Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials. Journal of Global Antimicrobial Resistance 34, pages 46-58.
Crossref
Fabio Borgonovo, Massimiliano Quici, Antonio Gidaro, Davide Giustivi, Dario Cattaneo, Cristina Gervasoni, Maria Calloni, Elena Martini, Leyla La Cava, Spinello Antinori, Chiara Cogliati, Andrea Gori & Antonella Foschi. (2023) Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review. Antibiotics 12:8, pages 1338.
Crossref
Marie Warrer Munch, Anders Granholm, Andreas Bender Jonsson, Fredrik Sjövall, Marie Helleberg, Frederik Boëtius Hertz, Jakob Steen Andersen, Morten Steensen, Michael Patrick Achiam, Anders Perner & Morten Hylander Møller. (2023) Piperacillin/tazobactam versus carbapenems in patients with severe bacterial infections: A systematic review with meta‐analysis. Acta Anaesthesiologica Scandinavica 67:7, pages 853-868.
Crossref
Chienhsiu Huang, Ihung Chen & Yalun Yang. (2022) Doripenem in the Treatment of Patients with Nosocomial Pneumonia: A Meta-Analysis. Journal of Clinical Medicine 11:14, pages 4014.
Crossref
Marya D. Zilberberg, Brian H. Nathanson, Laura A. Puzniak & Andrew F. Shorr. (2021) Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012–2019. Critical Care Medicine 50:3, pages 460-468.
Crossref
Marya D. Zilberberg, Brian H. Nathanson, Laura A. Puzniak & Andrew F. Shorr. (2022) Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014–2019. Infection Control & Hospital Epidemiology 43:3, pages 277-283.
Crossref
Ranganathan N. Iyer. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology 3 63 .
Donald J. AbrahamSebastian A. Testero, Leticia I. Llarrull, Jed F. Fisher & Shahriar Mobashery. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 1 188 .
Mackenzie Howatt, Michael Klompas, Andre C. Kalil, Mark L. Metersky & John Muscedere. (2021) Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia. Chest 159:3, pages 1041-1054.
Crossref
Marin H Kollef, Álvaro Réa-Neto, Richard G Wunderink, Christopher J Bruno & Elizabeth G Rhee. (2020) Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia – Authors' reply. The Lancet Infectious Diseases 20:1, pages 20-21.
Crossref
Hung-Jen Tang & Chih-Cheng Lai. (2020) Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia. The Lancet Infectious Diseases 20:1, pages 20.
Crossref
Wang-Da Liu, Ming-Chieh Shih, Yu-Chung Chuang, Jann-Tay Wang & Wang-Huei Sheng. (2019) Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia. Journal of Microbiology, Immunology and Infection 52:5, pages 788-795.
Crossref
Chih-Cheng Lai, I-Ling Cheng, Yu-Hung Chen & Hung-Jen Tang. (2019) The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 8:7, pages 958.
Crossref
George H Talbot, Anita Das, Stephanie Cush, Aaron Dane, Michele Wible, Roger Echols, Antoni Torres, Sue Cammarata, John H Rex, John H Powers, Thomas Fleming, Jeffrey Loutit & Steve Hoffmann. (2019) Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. The Journal of Infectious Diseases 219:10, pages 1536-1544.
Crossref
J Nicholas O'Donnell, Nathaniel J Rhodes, Jenna Lopez, Rebecca Jett & Marc H Scheetz. (2018) Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis. International Journal of Antimicrobial Agents 52:4, pages 451-458.
Crossref
Jeung Yun Kang, Kyung A Lee, Jae Song Kim, Soo Hyun Kim & Eun Sun Son. (2018) Comparison of Piperacillin/Tazobactam Dosing (13.5 g/day vs. 18 g/day) for the Treatment of Hospital-Acquired Pneumonia and Ventilator-associated Pneumonia in Intensive Care Unit . Korean Journal of Clinical Pharmacy 28:3, pages 167-173.
Crossref
Samuel Deshayes, Antoine Coquerel & Renaud Verdon. (2017) Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review. Drug Safety 40:12, pages 1171-1198.
Crossref
H. Bao, Y. Lv, D. Wang, J. Xue & Z. Yan. (2016) Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. European Journal of Clinical Microbiology & Infectious Diseases 36:3, pages 459-466.
Crossref
Chien-Ming Chao, Chi-Chung Chen, Hui-Ling Huang, Yin-Ching Chuang, Chih-Cheng Lai & Hung-Jen Tang. (2016) Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections. PLOS ONE 11:12, pages e0167522.
Crossref
Lauren E Arthur, Russell S Kizor, Adrian G Selim, Mieke L van Driel & Leonardo Seoane. (2016) Antibiotics for ventilator-associated pneumonia. Cochrane Database of Systematic Reviews 2016:10.
Crossref
Andre C. Kalil, Mark L. Metersky, Michael Klompas, John Muscedere, Daniel A. Sweeney, Lucy B. Palmer, Lena M. Napolitano, Naomi P. O'Grady, John G. Bartlett, Jordi Carratalà, Ali A. El Solh, Santiago Ewig, Paul D. Fey, Thomas M. FileJrJr, Marcos I. Restrepo, Jason A. Roberts, Grant W. Waterer, Peggy Cruse, Shandra L. Knight & Jan L. Brozek. (2016) Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases 63:5, pages e61-e111.
Crossref
Kazuhiro Yatera, Keisuke Naito, Shingo Noguchi, Kentarou Akata, Kei Yamasaki, Chinatsu Nishida, Toshinori Kawanami, Noriho Sakamoto, Takashi Kido, Hiroshi Ishimoto & Hiroshi Mukae. (2016) Clinical efficacy and safety of high-dose doripenem in Japanese patients with pneumonia. Journal of Infection and Chemotherapy 22:3, pages 137-142.
Crossref
Christopher R. Cannavino, Bibiana Castaneda-Ruiz, Rebecca Redman, Oscar Go, Iolanda Cirillo, Vidmantas Barauskas, Ganna Senatorova, Andrzej Emeryk & John S. Bradley. (2015) Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia. Pediatric Infectious Disease Journal 34:11, pages 1264-1267.
Crossref
Raoul SutterStephan RüeggSarah Tschudin-Sutter. (2015) Seizures as adverse events of antibiotic drugs. Neurology 85:15, pages 1332-1341.
Crossref
Kazuhiro Kamata, Hiromichi Suzuki, Koji Kanemoto, Yasuharu Tokuda, Seiji Shiotani, Yumi Hirose, Masatsune Suzuki & Hiroichi Ishikawa. (2015) Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia. Journal of Infection and Chemotherapy 21:8, pages 596-603.
Crossref
Xiao-Yu Qu, Ting-Ting Hu & Wei Zhou. (2015) A meta-analysis of efficacy and safety of doripenem for treating bacterial infections. The Brazilian Journal of Infectious Diseases 19:2, pages 156-162.
Crossref
Tomer Avni, Shahaf Shiver-Ofer, Leonard Leibovici, Evelina Tacconelli, Giulia DeAngelis, Barry Cookson, Leonardo Pagani & Mical Paul. (2015) Participation of Elderly Adults in Randomized Controlled Trials Addressing Antibiotic Treatment of Pneumonia. Journal of the American Geriatrics Society 63:2, pages 233-243.
Crossref
Shachaf Shiber, Dafna Yahav, Tomer Avni, Leonard Leibovici & Mical Paul. (2015) β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy 70:1, pages 41-47.
Crossref
Joan P. Cannon, Todd A. Lee, Nina M. Clark, Paul Setlak & Shellee A. Grim. (2014) The risk of seizures among the carbapenems: a meta-analysis. Journal of Antimicrobial Chemotherapy 69:8, pages 2043-2055.
Crossref
S. S. Awad, A. H. Rodriguez, Y.-C. Chuang, Z. Marjanek, A. J. Pareigis, G. Reis, T. W. L. Scheeren, A. S. Sanchez, X. Zhou, M. Saulay & M. Engelhardt. (2014) A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia. Clinical Infectious Diseases 59:1, pages 51-61.
Crossref
T. Avni, S. Shiber-Ofer, L. Leibovici & M. Paul. (2013) Assessment of bias in outcomes reported in trials on pneumonia: a systematic review. European Journal of Clinical Microbiology & Infectious Diseases 33:6, pages 969-974.
Crossref
Mahiran Mustafa, Wai Ming Chan, Christopher Lee, Eddy Harijanto, Chian Min Loo, Nguyen Van Kinh, Nguyen Dat Anh & Jemelyn Garcia. (2014) A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study). International Journal of Antimicrobial Agents 43:4, pages 353-360.
Crossref
Michael B. Kays, Megan R. Fleming, S. Christian Cheatham, Eun Kyoung Chung & Joetta M. Juenke. (2013) Comparative Pharmacokinetics and Pharmacodynamics of Doripenem and Meropenem in Obese Patients. Annals of Pharmacotherapy 48:2, pages 178-186.
Crossref
T. W. Felton, J. Goodwin, L. O'Connor, A. Sharp, L. Gregson, J. Livermore, S. J. Howard, M. N. Neely & W. W. Hope. (2013) Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 57:12, pages 5811-5819.
Crossref
Francisco Javier Carrera-Hueso, Rafael Ferriols-Lisart, José A Carrera-Hueso, Jaime E Poquet Jornet, Carmen Escoms-Moreno, Auxiliadora Ramón-Barrios & Manuel Hernández Pérez. (2013) Coste-efectividad de doripenem o imipenem en la neumonía asociada al respirador. PharmacoEconomics Spanish Research Articles 10:4, pages 131-140.
Crossref
Silvia Garazzino, Irja Lutsar, Chiara Bertaina, Pier-Angelo Tovo & Mike Sharland. (2013) New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000—Why aren’t we doing better?. International Journal of Antimicrobial Agents 42:2, pages 99-118.
Crossref
Masanori Harada, Naoki Inui, Takafumi Suda, Yutaro Nakamura, Toshihiro Wajima, Yumiko Matsuo & Kingo Chida. (2013) Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia. International Journal of Antimicrobial Agents 42:2, pages 149-154.
Crossref
Lama Hsaiky, Kyle P Murray, Lianne Kokoska, Neha Desai & Raymond Cha. (2013) Standard Versus Prolonged Doripenem Infusion for Treatment of Gram-Negative Infections. Annals of Pharmacotherapy 47:7-8, pages 999-1006.
Crossref
Dennis A.K. Rice, Koné Kaniga, Michael Lee & Rebecca Redman. (2013) Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials. International Journal of Antimicrobial Agents 41:4, pages 388-392.
Crossref
Matteo Bassetti, Maria Merelli, Chiara Temperoni & Augusta Astilean. (2013) New antibiotics for bad bugs: where are we?. Annals of Clinical Microbiology and Antimicrobials 12:1, pages 22.
Crossref
Fumi Karino, Kiyotaka Miura, Hiroshi Fuchita, Naoya Koba, Emiko Nishikawa, Takamasa Hotta, Tamio Okimoto, Shinichi Iwamoto, Yukari Tsubata, Mitsuhiro Tada, Shunichi Hamaguchi, Takeshi Honda, Miki Ohe, Akihisa Sutani, Takashige Kuraki, Hiroyasu Takeyama & Takeshi Isobe. (2013) Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. Journal of Infection and Chemotherapy 19:5, pages 909-915.
Crossref
Jomy M. George, Trent G. Towne & Keith A. Rodvold. (2012) Prolonged Infusions of β‐Lactam Antibiotics: Implication for Antimicrobial Stewardship. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:8, pages 707-721.
Crossref
Marin H Kollef, Jean Chastre, Marc Clavel, Marcos I Restrepo, Bart Michiels, Koné Kaniga, Iolanda Cirillo, Holly Kimko & Rebecca Redman. (2012) A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care 16:6, pages R218.
Crossref
Brett J. Balderson, Mary E. D. Yates, Neelu P. Patil & Katie J. Suda. (2011) Evaluation of doripenem utilization and susceptibilities at a large urban hospital. International Journal of Clinical Pharmacy 33:6, pages 958-963.
Crossref
Jose A. Bazan, Stanley I. Martin & Kenneth M. Kaye. (2011) Newer Beta-lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, and Cefepime. Medical Clinics of North America 95:4, pages 743-760.
Crossref
April D. Miller, Amanda M. Ball, P. Brandon Bookstaver, Emily K. Dornblaser & Charles L. Bennett. (2012) Epileptogenic Potential of Carbapenem Agents: Mechanism of Action, Seizure Rates, and Clinical Considerations. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:4, pages 408-423.
Crossref
Elias B. Chahine, Mary J. Ferrill & Mara N. Poulakos. (2010) Doripenem: A new carbapenem antibiotic. American Journal of Health-System Pharmacy 67:23, pages 2015-2024.
Crossref
Michael PfallerDaryl DePestel & David Paterson. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition 514 525 .
Donald J. AbrahamSebastian A. Testero, Jed F. Fisher & Shahriar Mobashery. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 257 402 .
M. D. Parkins & J. S. Elborn. (2010) Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. Journal of Antimicrobial Chemotherapy 65:9, pages 1853-1861.
Crossref
María José Fresnadillo Martínez, María Inmaculada García García, Enrique García Sánchez & José Elías García Sánchez. (2010) Los carbapenems disponibles: Propiedades y diferencias. Enfermedades Infecciosas y Microbiología Clínica 28, pages 53-64.
Crossref
Matthew E. Falagas, Evridiki K. Vouloumanou, Konstantinos Sgouros, Stavros Athanasiou, George Peppas & Ilias I. Siempos. (2010) Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents. International Journal of Antimicrobial Agents 36:1, pages 1-13.
Crossref
Mahesh N. Samtani, Robert Flamm, Koné Kaniga & Partha Nandy. (2010) Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients. Antimicrobial Agents and Chemotherapy 54:6, pages 2360-2364.
Crossref
Koné Kaniga, Robert Flamm, Shin-Yir Tong, Michael Lee, Ian Friedland & Rebecca Redman. (2010) Worldwide Experience with the Use of Doripenem against Extended-Spectrum-β-Lactamase-Producing and Ciprofloxacin-Resistant Enterobacteriaceae : Analysis of Six Phase 3 Clinical Studies . Antimicrobial Agents and Chemotherapy 54:5, pages 2119-2124.
Crossref
Alfred Sorbello, Scott Komo & Thamban Valappil. (2010) Noninferiority Margin for Clinical Trials of Antibacterial Drugs for Nosocomial Pneumonia. Drug Information Journal 44:2, pages 165-176.
Crossref
Peter J. Petersen, Margareta Tuckman & Hal Jones. (2010) In vitro Activity of Tigecycline Against Patient Isolates Collected during Phase 3 Clinical Trials for Hospital Acquired Pneumonia. Infectious Disease Reports 2:1, pages e1.
Crossref
Kristine Willett, Kirthana RamanJessica Nichols & Cheryl Durand. (2010) Doripenem: The Newest Addition to Carbapenem Antibiotics. Journal of Pharmacy Technology 26:1, pages 14-21.
Crossref
B.-P. Guery. (2009) Le doripénème : quelle place pour un nouveau carbapénème ?. Médecine et Maladies Infectieuses 39:12, pages 871-876.
Crossref
Jose A. Bazan, Stanley I. Martin & Kenneth M. Kaye. (2009) Newer Beta-lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, and Cefepime. Infectious Disease Clinics of North America 23:4, pages 983-996.
Crossref
. (2009) The changing face of antibiotic therapy. British Journal of Hospital Medicine 70:10, pages 586-587.
Crossref
Jared L. Crandon, Catharine C. Bulik & David P. Nicolau. (2009) In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa . Antimicrobial Agents and Chemotherapy 53:10, pages 4352-4356.
Crossref
George G. Zhanel, Nzeera Ketter, Ethan Rubinstein, Ian Friedland & Rebecca Redman. (2009) Overview of Seizure-Inducing Potential of Doripenem. Drug Safety 32:9, pages 709-716.
Crossref
Emilio Bouza & Almudena Burillo. (2009) Advances in the prevention and management of ventilator-associated pneumonia. Current Opinion in Infectious Diseases 22:4, pages 345-351.
Crossref
A. A. El Solh & A. Alhajhusain. (2009) Update on the treatment of Pseudomonas aeruginosa pneumonia. Journal of Antimicrobial Chemotherapy 64:2, pages 229-238.
Crossref
Pavani Reddy, Smitha Chadaga & Gary A. Noskin. (2009) Antibiotic considerations in the treatment of multidrug‐resistant (MDR) pathogens: A case‐based review. Journal of Hospital Medicine 4:6.
Crossref
Rodrigo E. Mendes, Paul R. Rhomberg, Jan M. Bell, John D. Turnidge & Helio S. Sader. (2009) Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagnostic Microbiology and Infectious Disease 63:4, pages 415-425.
Crossref
Ronald N. Jones, Jan M. Bell, Helio S. Sader, John D. Turnidge & Matthew G. Stilwell. (2009) In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens. Diagnostic Microbiology and Infectious Disease 63:4, pages 434-439.
Crossref
Anthony M. NicasioJoseph L. KutiDavid P. Nicolau. (2009) Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. Clinical Medicine. Therapeutics 1, pages CMT.S2062.
Crossref
S.James Matthews & Jason W. Lancaster. (2009) Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clinical Therapeutics 31:1, pages 42-63.
Crossref
Drosos E. Karageorgopoulos & Matthew E. Falagas. (2009) New antibiotics: optimal use in current clinical practice. International Journal of Antimicrobial Agents 34, pages S55-S62.
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:1.
Crossref
Susan J Keam. (2008) Doripenem. Drugs 68:14, pages 2021-2057.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.